LeMaitre Vascular (NASDAQ:LMAT) & Futureworld (OTCMKTS:FWDG) Head-To-Head Survey

Futureworld (OTCMKTS:FWDG) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends.

Volatility and Risk

Futureworld has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Institutional and Insider Ownership

84.6% of LeMaitre Vascular shares are owned by institutional investors. 9.5% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Futureworld and LeMaitre Vascular, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Futureworld	0	0	0	0	0.00
LeMaitre Vascular	0	4	2	0	2.33

LeMaitre Vascular has a consensus target price of $97.83, indicating a potential upside of 18.49%. Given LeMaitre Vascular’s stronger consensus rating and higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Futureworld.

Profitability

This table compares Futureworld and LeMaitre Vascular’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Futureworld	N/A	N/A	N/A
LeMaitre Vascular	19.96%	13.53%	9.78%

Valuation & Earnings

This table compares Futureworld and LeMaitre Vascular”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Futureworld	N/A	N/A	N/A	N/A	N/A
LeMaitre Vascular	$219.86 million	8.48	$44.04 million	$1.98	41.70

LeMaitre Vascular has higher revenue and earnings than Futureworld.

Summary

LeMaitre Vascular beats Futureworld on 10 of the 10 factors compared between the two stocks.

About Futureworld

FutureWorld Corp., together with its subsidiaries, focuses on the identification, acquisition, development, and commercialization of hemp/cannabis products, services, and technologies worldwide. The company provides smart sensor technology, communication network, surveillance security, data analysis for smart cultivation, and consultation for the industrial hemp and legal medicinal marijuana. It offers personal and professional tetrahydrocannabinoil and Cannabidiol test kits; pharmaceutical grade CBD oil solutions; URVape vaporizer pens, which are oil vaporizers for the e-cigarette, cannabis, and herbal vaping industry; CaNNaLyTiX, a dashboard controller system that allows various computer systems to be integrated throughout a cultivator's infrastructures; CaNNaTRAK, the barcode and RFID tracking systems for keeping seed to sale tracking of hemp/cannabis; and SPIDer (secure perimeter intrusion detection network), a system to meet the needs of theft and malicious attacks. The company also provides SmartSense, which offers wireless security and smart sensor mesh network for precision agriculture, irrigation systems, and greenhouses for the hemp industry; SmartNergy that offers tools to analyze various aspects of a cultivator's energy usage; and CaNNaBoX machine, which operates with the swipe of a card to verify identity, age, and prescription information of a medical marijuana patient before releasing measured packages of marijuana. Its target customers include consumers via Internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, affiliate sales, and master distributors. The company was formerly known as FutureWorld Energy, Inc. and changed its name to FutureWorld Corp. in June 2014. FutureWorld Corp. was founded in 2002 and is based in Saint Petersburg, Florida.

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.